Absci Corporation Q2 2025 Results: Revenue Falls to $0.6M, Net Loss Widens to $30.6M

Reuters
08/13
Absci Corporation <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Results: Revenue Falls to $0.6M, Net Loss Widens to $30.6M

Absci Corporation, a clinical-stage biopharmaceutical company, reported its financial results for the second quarter of 2025. The company recorded a revenue of $0.6 million for the quarter ended June 30, 2025, a decrease from $1.3 million in the same period the previous year. The net loss for the quarter was $30.6 million, compared to a net loss of $24.8 million in the second quarter of 2024. Research and development expenses increased to $20.5 million from $15.3 million, attributed to the advancement of Absci's internal programs and related costs. Selling, general, and administrative expenses decreased to $8.5 million from $9.3 million due to a reduction in stock compensation expense. Significantly, Absci strengthened its financial position by raising approximately $64 million in July 2025 through a public offering and the use of its at-the-market facility. As a result, the company anticipates that its cash, cash equivalents, and short-term investments, which stood at $117.5 million as of June 30, 2025, will be sufficient to fund operations into the first half of 2028. In addition to its financial results, Absci announced an expanded collaboration with Almirall, with a new focus on a second target for dermatological indications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Absci Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9510409-en) on August 12, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10